Cited 3 times in
Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강석민 | - |
dc.contributor.author | 김창수 | - |
dc.date.accessioned | 2017-02-27T07:36:02Z | - |
dc.date.available | 2017-02-27T07:36:02Z | - |
dc.date.issued | 2016 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/146931 | - |
dc.description.abstract | BACKGROUND: The angiotensin receptor antagonist fimasartan lowered blood pressure (BP) in a previous large population study. The purpose of this study was to evaluate whether fimasartan treatment for 3 months affects clinical and home BP variability in addition to reducing BP. METHODS: The study enrolled 1,396 patients (mean age 56.2±10.0 years; males 53.6%) with mild-to-moderate hypertension who had a complete set of home BP measurements (morning and evening) and metabolic risk evaluation. During the 3 months of study, fimasartan alone was used to control BP at a daily dose of 30-120 mg. Clinical and home BP measurements were performed before and after the 3-month treatment. BP variability included beat-to-beat variability (clinical) and day-to-day variability (home). RESULTS: Fimasartan reduced BP after 3 months of treatment. The average reduction of clinical systolic BP (c-SBP) was 15.08±18.36 mmHg (P<0.0001), and the average reduction of morning home SBP (m-SBP) was 11.49±19.33 mmHg (P<0.0001). Beat-to-beat variability as standard deviation (SD) of c-SBP was reduced from 4.56±3.22 to 4.24±3.11 mmHg (P=0.0026). Day-to-day variability as SD of m-SBP was reduced from 7.92±6.74 to 6.95±4.97 mmHg (P<0.0001). Multiple regression analysis revealed an independent association between the change in the SD of c-SBP and the change in c-SBP (P=0.0268) and, similarly, between the change in the SD of m-SBP and the change in m-SBP (P=0.0258), after adjusting for age, sex, body mass index, and change in mean BP. CONCLUSION: This study indicated that 3 months of fimasartan treatment reduced day-to-day BP variability independent of BP reduction in patients with hypertension. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1573~1580 | - |
dc.language | English | - |
dc.publisher | Dove Press Limited | - |
dc.relation.isPartOf | DRUG DESIGN DEVELOPMENT AND THERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Angiotensin Receptor Antagonists/chemistry | - |
dc.subject.MESH | Angiotensin Receptor Antagonists/therapeutic use* | - |
dc.subject.MESH | Antihypertensive Agents/therapeutic use* | - |
dc.subject.MESH | Biphenyl Compounds/chemistry | - |
dc.subject.MESH | Biphenyl Compounds/pharmacology* | - |
dc.subject.MESH | Blood Pressure/drug effects* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypertension/drug therapy* | - |
dc.subject.MESH | Pyrimidines/chemistry | - |
dc.subject.MESH | Pyrimidines/pharmacology* | - |
dc.subject.MESH | Tetrazoles/chemistry | - |
dc.subject.MESH | Tetrazoles/pharmacology* | - |
dc.title | Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension. | - |
dc.type | Article | - |
dc.publisher.location | New Zealand | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Mi-Seung Shin | - |
dc.contributor.googleauthor | Dae Ryong Kang | - |
dc.contributor.googleauthor | Changsoo Kim | - |
dc.contributor.googleauthor | Eun Joo Cho | - |
dc.contributor.googleauthor | Ki-Chul Sung | - |
dc.contributor.googleauthor | Seok-Min Kang | - |
dc.contributor.googleauthor | Dong-Soo Kim | - |
dc.contributor.googleauthor | Seung Jae Joo | - |
dc.contributor.googleauthor | Seung Hwan Lee | - |
dc.contributor.googleauthor | Kyung-Kuk Hwang | - |
dc.contributor.googleauthor | Jeong Bae Park | - |
dc.identifier.doi | 10.2147/DDDT.S107433 | - |
dc.contributor.localId | A00037 | - |
dc.contributor.localId | A01042 | - |
dc.relation.journalcode | J02859 | - |
dc.identifier.eissn | 1177-8881 | - |
dc.identifier.pmid | 27217724 | - |
dc.subject.keyword | angiotensin receptor blockers | - |
dc.subject.keyword | blood pressure variability | - |
dc.subject.keyword | hypertension | - |
dc.contributor.alternativeName | Kang, Seok Min | - |
dc.contributor.alternativeName | Kim, Chang Soo | - |
dc.contributor.affiliatedAuthor | Kang, Seok Min | - |
dc.contributor.affiliatedAuthor | Kim, Chang Soo | - |
dc.citation.volume | 10 | - |
dc.citation.startPage | 1573 | - |
dc.citation.endPage | 1580 | - |
dc.identifier.bibliographicCitation | DRUG DESIGN DEVELOPMENT AND THERAPY, Vol.10 : 1573-1580, 2016 | - |
dc.date.modified | 2017-02-24 | - |
dc.identifier.rimsid | 46496 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.